Veracyte, Inc. (VCYT)
NASDAQ: VCYT · IEX Real-Time Price · USD
20.19
+0.06 (0.30%)
At close: May 2, 2024, 4:00 PM
19.96
-0.23 (-1.14%)
After-hours: May 2, 2024, 4:55 PM EDT
Veracyte Employees
Veracyte had 815 employees on December 31, 2023. The number of employees increased by 28 or 3.56% compared to the previous year.
Employees
815
Change (1Y)
28
Growth (1Y)
3.56%
Revenue / Employee
$443,007
Profits / Employee
-$91,293
Market Cap
1.52B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 815 | 28 | 3.56% |
Dec 31, 2022 | 787 | 26 | 3.42% |
Dec 31, 2021 | 761 | 441 | 137.81% |
Dec 31, 2020 | 320 | -34 | -9.60% |
Dec 31, 2019 | 354 | 84 | 31.11% |
Dec 31, 2018 | 270 | 24 | 9.76% |
Dec 31, 2017 | 246 | 30 | 13.89% |
Dec 31, 2016 | 216 | 24 | 12.50% |
Dec 31, 2015 | 192 | 25 | 14.97% |
Dec 31, 2014 | 167 | 52 | 45.22% |
Dec 31, 2013 | 115 | 16 | 16.16% |
Dec 31, 2012 | 99 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
National HealthCare | 13,123 |
LeMaitre Vascular | 630 |
InMode | 581 |
Dynavax Technologies | 408 |
Ardelyx | 267 |
Day One Biopharmaceuticals | 155 |
Kura Oncology | 142 |
Neumora Therapeutics | 124 |
VCYT News
- 10 days ago - Veracyte to Release First Quarter 2024 Financial Results on May 7, 2024 - Business Wire
- 10 days ago - New Study Shows Veracyte's Decipher Prostate Test is Prognostic for Prostate Cancer Progression Among Patients Undergoing Active Surveillance - Business Wire
- 16 days ago - Veracyte Announces that Nine Studies Reinforcing the Value of Decipher Prostate and Decipher Bladder Testing Will Be Presented at AUA 2024 - Business Wire
- 2 months ago - Veracyte's Decipher Prostate Test Receives Highest Evidence-Level Rating Among Molecular Tests in Updated Prostate Cancer NCCN Guidelines - Business Wire
- 2 months ago - Veracyte Announces Fourth Quarter and Full-Year 2023 Financial Results - Business Wire
- 2 months ago - Veracyte to Participate in the Raymond James 45th Annual Institutional Investors Conference - Business Wire
- 3 months ago - Veracyte to Release Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024 - Business Wire
- 3 months ago - Veracyte Completes Acquisition of C2i Genomics - Business Wire